Form 8-K - Current report:
SEC Accession No. 0001213900-18-002270
Filing Date
2018-02-26
Accepted
2018-02-26 09:08:12
Documents
6
Period of Report
2018-02-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k022618_actiniumpharma.htm 8-K 31741
2 CERTIFICATE OF AMENDMENT TO ACTINIUM'S CERTIFICATE OF INCORPORATION, AS AMENDED, f8k022618ex3-1_actinium.htm EX-3.1 7917
3 FORM OF NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE f8k022618ex4-1_actinium.htm EX-4.1 26231
4 PRESS RELEASE OF ACTINIUM PHARMACEUTICALS, INC., DATED FEBRUARY 26, 2018 f8k022618ex99-1_actinium.htm EX-99.1 32978
5 FORM OF BENEFICIAL OWNER ELECTION FORM f8k022618ex99-2_actinium.htm EX-99.2 11766
6 GRAPHIC ex99-1_001.jpg GRAPHIC 26576
  Complete submission text file 0001213900-18-002270.txt   148648
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 18638800
SIC: 2834 Pharmaceutical Preparations